Content Type: Article

  • Florida Set to Repeal Diligent Search for Surplus Lines Policies

    Florida Set to Repeal Diligent Search for Surplus Lines Policies

    ARTICLE / CLIENT ALERT

    Florida Set to Repeal Diligent Search for Surplus Lines Policies

    May 16, 2025

    Read time: 3 min

    Key takeaways
    Overview

    On May 2, 2025, the Florida Senate voted to pass Senate Bill (SB) 1549, which would repeal the requirement for insurance producers to perform a diligent search of the admitted market before placing Florida risks with a surplus lines carrier. Virginia, Mississippi, Louisiana, and Wisconsin have already repealed their diligent search requirements for surplus lines policies. With Florida joining their ranks, it becomes the state with the largest share of the surplus lines market to have repealed its diligent search requirement to date.

    Current Florida law requires retail or producing agents to perform and document a “diligent search” and obtain at least three declinations from admitted insurers actually writing the type of coverage sought before a surplus lines producer can offer the risk to a surplus lines insurer. (Currently, for residential property policies with a replacement cost of $700,000 or more, only one declination is required.) SB 1549 would eliminate the diligent search requirement for all Florida surplus lines risks, a significant move for a state with more than $17 billion in surplus lines premium in 2024.

    SB 1549 also amends the disclosure statement, which Florida surplus lines producers are required to provide to each insured, adding the following sentence: “Additionally, surplus lines insurers’ rates and forms are not approved by any Florida regulatory agency.” The bill goes on to state that, if the acknowledgment of the disclosure is signed by the policyholder, “the insured is presumed to have been informed and to know that other coverage may be available.”

    SB 1549 was also passed by the Florida House and is awaiting signature by Governor Ron DeSantis. Assuming he signs the legislation, it will take effect July 1, 2025.

    In depth
    Authors

    Andrea T. Best

    Partner

    London – 22 Bishopsgate

    H. Michael Byrne

    Partner

    New York – One Vanderbilt Avenue

    Michael R. Halsband

    Partner

    New York – One Vanderbilt Avenue

    Thomas M. Dawson

    Partner

    New York – One Vanderbilt Avenue

    More insights

  • DOJ Unveils New Plan for White-Collar Crime and Corporate Enforcement

    DOJ Unveils New Plan for White-Collar Crime and Corporate Enforcement

    CLIENT ALERT / US POLICY

    DOJ Unveils New Plan for White-Collar Crime and Corporate Enforcement

    May 14, 2025

    Read time: 9 min

    Key takeaways
    Overview

    The US Department of Justice’s (DOJ’s) current approach to corporate criminal enforcement has come into focus with the issuance of a new White-Collar Enforcement Plan and several revised policy documents. The changes, which represent the first substantive updates to DOJ’s white-collar enforcement policies under the new presidential administration, were announced by Matthew R. Galeotti, Head of the Criminal Division, on May 12, 2025.

    Galeotti expressed that the Criminal Division is “turning a new page on white-collar and corporate enforcement” due to a perception that prior approaches have “come at too high a cost for businesses and American enterprise.” The new approach attempts to address the burden that investigations, enforcement, and post-resolution requirements can place on US businesses, while also underscoring that DOJ remains committed to enforcement in the white-collar space.

    In addition to the White-Collar Enforcement Plan, DOJ issued revised versions of the following:

    In many respects, the revised policies cover familiar ground. They seek to incentivize voluntary self-disclosure, increase transparency for companies entering into criminal resolutions with DOJ, ensure that monitors are deployed appropriately, and reward whistleblowers. Priority focus areas for enforcement include some familiar topics (such as waste, fraud, and abuse) and others that are consistent with administration priorities (such as trade and customs fraud, including tariff evasion). There are also some significant shifts reflected in the revised policies, including:

    • An increased openness to early termination of corporate criminal resolutions;
    • A directive to prosecutors to minimize the length of investigations;
    • Fee caps for monitorships, and fewer monitors overall; and
    • A more definitive path to declination, among other things.

    These and other changes are discussed in more detail below.

    In depth

    White-Collar Enforcement Plan

    DOJ’s current approach to corporate criminal enforcement is broadly outlined in a memo to Criminal Division personnel titled “Focus, Fairness, and Efficiency in the Fight Against White-Collar Crime.” The memo, also referred to as the “White Collar Enforcement Plan,” starts by acknowledging that white-collar crime “poses a significant threat to U.S. interests.” However, it also states that “overbroad and unchecked” enforcement can burden US businesses and harm US interests. The memo then describes several policy changes that are aimed at addressing this concern, including:

    • New priority areas of focus: The Criminal Division will prioritize investigating and prosecuting white-collar crimes in the following areas:
      • Waste, fraud, and abuse, including healthcare fraud and federal program and procurement fraud;
      • Trade and customs fraud, including tariff evasion;
      • Fraud perpetrated through variable interest entities (VIEs), including, but not limited to, offering fraud, “ramp and dumps,” elder fraud, securities fraud, and other market manipulation schemes;
      • Fraud that victimizes US investors, individuals, and markets, including, but not limited to, Ponzi schemes, investment fraud, elder fraud, servicemember fraud, and fraud that threatens the health and safety of consumers;
      • Conduct that threatens national security, including threats to the US financial system by gatekeepers, such as financial institutions and their insiders that commit sanctions violations or enable transactions by cartels, transnational criminal organizations (TCOs), hostile nation-states, and/or foreign terrorist organizations;
      • Material support by corporations to foreign terrorist organizations, including recently designated cartels and TCOs;
      • Complex money laundering, including Chinese Money Laundering Organizations and other organizations involved in laundering funds used in the manufacturing of illegal drugs;
      • Violations of the Controlled Substances Act and the Federal Food, Drug, and Cosmetic Act (FDCA), including in connection with fentanyl and opioids;
      • Bribery and associated money laundering that impacts US national interests, undermines US national security, harms the competitiveness of US businesses, and enriches foreign corrupt officials; and
      • Crimes involving digital assets that victimize investors and consumers, use digital assets in furtherance of other criminal conduct, or facilitate significant criminal activity.

    It is notable that this list of priority areas for enforcement includes certain types of bribery and foreign corruption, given the pause that was placed on Foreign Corrupt Practices Act (FCPA) enforcement by an executive order in February 2025.

    • Early termination of corporate criminal resolutions: DOJ is currently reviewing the terms of all existing agreements between companies and the Fraud Section and/or the Money Laundering and Asset Recovery Section (MLARS) to determine whether early termination is appropriate. Going forward, the terms of such agreements should not exceed three years, and agreements should be assessed regularly to determine if they should be terminated early. Factors that weigh in favor of early termination include:
      • The duration of the post-resolution period;
      • Whether there has been a substantial reduction in the company’s risk profile;
      • The extent of remediation;
      • The maturity of the company’s compliance program; and
      • Whether the company self-reported the misconduct.
    • Minimizing the length of investigations: Criminal Division prosecutors must now “take all reasonable steps to minimize the length and collateral impact of their investigations” and “move expeditiously to investigate cases and make charging decisions.” DOJ will track investigations to ensure they are “swiftly concluded.”
    • Review of all existing monitorships: The Criminal Division is working with DOJ leadership to undertake an individualized review of all existing monitorships to determine whether each monitor is still necessary. In performing this review, DOJ is following principles outlined in the newly updated monitor selection memo, described in more detail below.

    The White Collar Enforcement Plan also discusses revisions to DOJ’s Corporate Enforcement and Voluntary Self-Disclosure Policy and monitor selection memo, which are discussed below.

    Corporate Enforcement and Voluntary Self-Disclosure Policy

    DOJ has long sought to incentivize voluntary self-disclosures, which are important to DOJ’s current goal of increasing efficiency in investigations, as they allow prosecutors to more quickly identify relevant facts and culpable individuals. The revised Corporate Enforcement and Voluntary Self-Disclosure Policy offers greater benefits to companies that voluntarily self-disclose misconduct, along with other changes:

    • Clearer path to declination: The path to a declination is now clearer under the revised Policy. The Criminal Division will decline to prosecute a company for criminal conduct when it voluntarily self-discloses, fully cooperates, timely and appropriately remediates, and there are no aggravating circumstances. This contrasts with the prior version of the Policy, which only promised a presumption of declination in such circumstances.
    • Fewer requirements to overcome aggravating factors: The revised Policy states that prosecutors have discretion to recommend a declination – even if aggravating factors are present – based on a weighing the severity of those factors against the company’s cooperation and remediation. The prior version of the Policy was more prescriptive and outlined specific requirements (such as “extraordinary” cooperation and “immediate” voluntary self-disclosure) for a company to qualify for a declination if aggravating factors were present.
    • More clarity for companies that do not qualify for declinations: Companies that do not meet all of the requirements for a declination now have more certainty about the form of resolution they will face. Specifically, companies that self-report misconduct in good faith, cooperate, and remediate, but do not meet all of the voluntary self-disclosure requirements (because, for instance, DOJ was already aware of the misconduct) will generally receive a non-prosecution agreement with a term fewer than three years, no independent compliance monitor, and a penalty reduction of 75% off the low end of the US Sentencing Guidelines fine range. The same is true where aggravating factors preclude a declination, but the company has voluntarily self-disclosed, cooperated, and remediated.
    • Streamlined requirements: The revised Policy is generally simpler than the prior version, although many of the principles remain the same. It also includes a flowchart to visually depict the path to a declination and other resolution types.

    Monitor Selection Memo

    The revised monitor selection memo updates the DOJ’s internal policies governing the imposition, selection, and oversight of independent compliance monitors in corporate criminal resolutions. While it retains the foundational principles outlined in prior guidance, the 2025 update introduces more detailed criteria for both the imposition and governance of monitorships.

    Additional considerations for imposing a monitor:

    • Impact on US interests: Prosecutors should evaluate whether imposing a monitor would mitigate the risk of repeat misconduct that significantly affects US interests, including sanctions evasion; threats to the US economy; foreign bribery that significantly impacts US interests; trade fraud; tariff evasion; procurement and healthcare fraud; and crimes supporting cartels, TCOs, narcotics trafficking, or terrorist organizations.
    • Third-party assistance in pre-resolution remediation: Prosecutors should assess whether a company’s voluntary, pre-resolution engagement of third-party consultants, auditors, or other experts to enhance or remediate its compliance program obviates the need for a monitor.

    Updated guidance on monitorship governance is as follows:

    • Monitor selection process: The selection process should include an evaluation of whether the candidate’s proposal is cost-efficient and avoids unnecessary burdens on the company’s operations.
    • Cost controls: Monitors must submit a detailed budget with their initial work plan, adhere to hourly rate caps, submit an updated budget for DOJ approval before beginning each phase of the monitorship, and obtain prior written approval from DOJ before being paid for any cost overruns.
    • Communication and oversight: Resolution agreements will require at least biannual tripartite meetings between DOJ, the company, and the monitor to align expectations, promote DOJ oversight, and prevent monitor overreach.

    Corporate Whistleblower Awards Pilot Program

    DOJ announced that it is leaving in place and expanding the Corporate Whistleblower Awards Pilot Program, which the Biden administration had announced earlier last year. The purpose of the program was to address misconduct that existing federal whistleblower programs do not already cover. The updated program expands the subject areas for qualifying whistleblower tips to align with DOJ’s recently announced enforcement priorities, adding the following subject areas:

    • Procurement and federal program fraud;
    • Trade, tariff, and customs fraud;
    • Violations of federal immigration law;
    • Violations involving sanctions or material support of foreign terrorist organizations; and
    • Violations that facilitate cartels and TCOs, including money laundering, narcotics, and Controlled Substances Act violations.

    If an individual helps DOJ discover previously unknown misconduct relating to the specified priority enforcement areas, the whistleblower can qualify for a monetary share of any resulting civil or criminal forfeiture action. However, DOJ’s announcement underscored that tips must result in forfeiture for whistleblowers to be eligible for a reward.

    Conclusion

    The announcement of the White Collar Enforcement Plan and associated policy revisions provide significant insight into how DOJ will approach white-collar enforcement in this administration. The coming months will offer additional clarity as we see these revised policies in practice. We also expect further guidance to be issued related to FCPA enforcement, consistent with the recent executive order on the topic. In the meantime, companies should stay vigilant to compliance risks, particularly in areas that DOJ has identified as priorities for investigation and prosecution.

    Authors

    Julian L. André

    Partner

    Los Angeles

    Matthew Madden

    Partner

    Chicago

    More insights

  • Unpacking the Latest Proposed CCPA Regulations

    Unpacking the Latest Proposed CCPA Regulations

    ARTICLE / CLIENT ALERT

    Unpacking the Latest Proposed CCPA Regulations

    May 13, 2025

    Read time: 10 min

    Key takeaways
    Overview

    On May 1, 2025, the California Privacy Protection Agency (CPPA) announced a major overhaul of its draft California Consumer Privacy Act (CCPA) regulations on automated decision-making, cybersecurity audits, risk assessments, and insurance. On May 9, 2025, the CPPA opened a truncated public comment period on the revised draft regulations, which will close on June 2, 2025. Our prior summaries (“Draft CCPA Regulations Stalled as Agency Struggles With Applicability of ADMT Rules” and “CPPA Releases Proposed Updates to CCPA Regulations and Unveils New Draft Privacy Assessment and ADM Rules”) addressed the broad reach of previous versions of these proposed regulations. While the CPPA has pulled back from many of the most ambitious – and onerous – parts of the proposed regulations, it is clear that the CPPA is moving to finalize these narrowed set of regulations by November 2025. So now is the time for companies subject to the CCPA to consider any final comments to the proposed regulations and begin planning for their implementation.

    In depth

    Changes to Existing Regulations

    Often lost in the discussion around the new aspects of the proposed CCPA regulations is that the CPPA is proposing many substantive changes to existing CCPA regulations as well. At least some of those proposed changes were removed in the latest round of draft proposals. Below are the key changes that remain:

    • Businesses that collect consent for a processing purpose must ensure that there is a method by which consumers can withdraw that consent “at any time.”
    • Links to a privacy policy must appear not just on the homepage but “any internet webpage where personal information is collected.”
    • Requests to opt-out must be the same or fewer steps than the method to opt-in (e.g., website cookies).
    • There are new rules for privacy disclosures related to connected and virtual reality devices.
    • Consumers can request personal information pursuant to an access request beyond information collected in the prior 12-month period.
    • An individual is not required to resubmit a data subject request when that consumer made the initial request through an agent.

    While these are the most significant changes to the existing regulations, the above is not an exhaustive list. The proposed regulations include numerous wordsmithing changes, clarifications and new illustrative examples as to how the CPPA expects the regulations to be followed.

    Cybersecurity Audits

    The latest proposals around cybersecurity audits will come as a welcome reprieve for many businesses. The CPPA is granting businesses more time to complete the initial audit and has pared back on some of the more onerous aspects of the prior proposals. Nonetheless, the cybersecurity audit requirement will be a burdensome task for many companies and will require significant time and resources to complete.

    Timing for First Cybersecurity Audit

    Welcome relief is that the latest proposed regulations introduce a phased timeline for the completion of cybersecurity audits. Cybersecurity audits for companies that have between $100 million and more than $1 billion in annual revenue must be completed by April 1, 2028. Companies in the $50 million to $100 million range must complete their first audit by April 1, 2029. Companies with under $50 million in annual revenue have until April 1, 2030, to complete their first audit. The revenue thresholds are based on a company’s 2026 gross revenue.

    On a going-forward basis, audits for the prior year will have to be completed by April of the current year. For example, the audit covering January 1, 2035, through January 1, 2036, must be completed by April 2036.

    Cybersecurity Audit Changes

    There are many changes to the actual implementation requirements of the cybersecurity audit as well, including:

    • Internal auditors will no longer have to report to the board of directors. Instead, the highest ranking auditor must report to a member of the business’s executive management team with responsibility for cybersecurity oversight.
    • The introspective aspects of the audit (i.e., why certain methods were chosen, outlining the methodology) have all been removed in the latest proposed regulations.
    • The auditor no longer needs to explain why a business does not implement one of the many cybersecurity safeguards pre-selected by the CCPA in the regulations (perhaps the most significant change). Rather, the auditor must only address the components that it deems are applicable to a business’s system.
    • The proposed regulations have withdrawn certain of the safeguards that drew the most criticism for being well outside market application (i.e., zero trust architecture).
    • The May 9, 2025, regulations require new descriptions of a company’s overall business information system and implementation of the company’s privacy program.
    • Businesses are no longer required to document why an alternative audit, such as the NIST Cybersecurity Framework 2.0, provides at least equivalent security to the requirements set out in the regulations. This means that businesses likely can leverage existing audits to meet the CCPA regulatory requirements.

    Finally, the content of the audit report has been modified to include:

    • A certification of completion must be submitted to the CPPA every April.
    • The certification must be completed by a member of the business’s executive management team responsible for cybersecurity implementation.
    • The certification must include the contact information for that individual, a statement of compliance, the time period covered by the audit, and an attestation by the signing individual.

    Risk Assessments

    When Required

    Although the automated decision-making technology (ADMT) obligations of the proposed CCPA regulations have been limited to a specific type of use of ADMT (discussed below), the newly proposed regulations include additional ADMT uses that must be subject to risk assessments. Risk assessments must be performed when a company:

    • Sells or shares personal information
    • Processes sensitive personal information (for any purpose)
    • Uses ADMT for significant decisions (discussed below)
    • Uses ADMT to infer or extrapolate a consumer’s intelligence, ability, aptitude, performance at work, and similar characteristics in the individual’s capacity as a job applicant, student, employee, or independent contractor
    • Uses ADMT to infer characteristics based on a person’s presence in a sensitive location (i.e., health, political, poverty, religious, or legal locations)
    • Uses personal information to train ADMT for a significant decision.

    Assessment Requirements

    The content of the assessments has been significantly updated in the newly proposed regulations. In particular, highly technical descriptions of the process and what could have been burdensome descriptions of the assessment process have been removed.

    Thankfully, the CPPA has added new language that recognizes that many businesses will have already been engaging in risk assessments to comply with other state consumer privacy laws. The proposed regulations acknowledge that companies can rely on those other assessments so long as they meet the requirements of the CCPA regulations.

    Timing for Completion of Assessments

    For processing that is already occurring prior to the effective date of the new regulations, businesses will have until December 31, 2027, to complete their assessments. If a business makes a material change to a process subject to a risk assessment, the business must update its risk assessment within 45 days of the change.

    Submission to the CPPA

    The submission process has also undergone significant change. For risk assessments conducted in 2026 and 2027, companies must submit information about the assessment, but not the assessment itself, to the CPPA by April 1, 2028. Businesses must provide a contact point, the time period covered by the submission, the number of risk assessments conducted by the business in the time period, whether the risk assessments covered the processing of personal information under the CCPA, an attestation, and the name of the person submitting the report. The person making the submission must be someone responsible for the business’s overall compliance with risk assessments under the CCPA regulations.

    Subsequent submissions are due in April of the following year (i.e., the 2035 yearly submission would be due April 1, 2036).

    Automated Decision-Making

    The headlines around ADMT changes include (1) that the proposed CCPA regulations remove all references to artificial intelligence (AI) and (2) the definition of what constitutes ADMT has been substantially narrowed. Both of these changes had been the target of much ink in the public comment period and even drew the ire of California’s governor, who wrote a letter to the CPPA suggesting that AI regulation was more appropriately handled by the legislature.

    Revised ADMT definition

    The definition of ADMT has been the source of much debate in the CCPA regulations. Up until recently, the definition was so broad that it could have included a calculator or an excel sheet with formulas in it. Thankfully, the newly proposed regulations have retreated from that absurd position.

    ADMT is now defined as technology that processes information “to replace human decisionmaking or substantially replace human decisionmaking.” The phrase “substantially replace human decisionmaking” is defined to mean a use of a technology output “without human involvement.” “Human involvement” requires that an individual understand the technology output, analyze it, and have the authority to change the output. While the definitions are more than a bit convoluted, the ADMT definition will now narrowly apply to “profiling” under the CCPA regulations and any technology that replaces human decision-making.

    Triggers for ADMT Requirements

    There have been substantial changes to what businesses must do when using ADMT. Most significantly, the requirements of the proposed CCPA regulations related to ADMT will now only apply if ADMT is used “to make a significant decision” concerning the consumer. All other uses of ADMT are excluded from the latest proposed regulations.

    Significant decisions concerning a consumer include decisions that result in the provision or denial of financial or lending services, housing, education enrollment or opportunities, employment or independent contracting opportunities or compensation, or healthcare services.

    For ADMT use that is subject to the newly proposed CCPA regulations, businesses must be in compliance by January 1, 2027, for existing ADMT use and at the time of use for all future ADMT operations after January 1, 2027.

    ADMT Consumer Rights

    Like other parts of the ADMT regulations, the new draft regulations include substantial, narrowing changes.

    Pre-Use Notice

    This must be provided at or before the point of collection or, if the information has already been collected, before the information is used in connection with covered ADMTs. The notice must include a description of the ADMT use, the right to opt-out and access the ADMT output, and how to exercise those rights. The notice also must include a statement that the consumer will not be retaliated against for exercising their rights. The new draft regulations also narrow the type of information that must be included about the ADMT, making it clear that no trade secrets or other sensitive information that would compromise a business’s ability to prevent fraud or defend the physical safety of people.

    Limitations on Consumer Rights

    The newly proposed regulations clarify that if ADMT is not used for a significant decision, businesses do not have to offer opt-out or access rights to consumers.

    Access Requests

    In response to an access request, the type of information that must be provided has been narrowed to:

    • The purpose for which the business used ADMT.
    • Information about the logic/how the ADMT process worked.
    • The outcome of the decision.
    • The business is prohibited from retaliating against the consumer for exercising their access right.

    Gone is the obligation to provide highly technical details to consumers.

    As with the changes to the pre-use notice, the newly proposed regulations make clear that businesses do not need to disclose trade secrets or information that would impact their ability to combat fraud or other security issues.

    What’s Next?


    Public comment on the new regulations is open through June 2, 2025. The staff and board of the CPPA have expressed an interest in having this rulemaking conclude by November 2025. To achieve that, we do not anticipate any further significant changes to the proposed regulations. As a result, it is time that businesses begin to prepare for the new, narrower CCPA regulations and make sure they are ready to implement the changes.

    If you are interested in commenting on the proposed regulations or are looking to begin adapting existing compliance mechanisms for the new regulations, please contact your regular McDermott lawyer or one of the authors of this article.

    Authors

    David P. Saunders

    Partner

    Chicago

    More insights

  • Transaction and Financing Trends in Life Sciences

    Transaction and Financing Trends in Life Sciences

    ARTICLE

    Transaction and Financing Trends in Life Sciences

    May 2025

    Read time: 6 min

    Key takeaways
    Overview

    In April, McDermott was pleased to once again host our annual European Health & Life Sciences Symposium in Paris. Welcoming a crowd of more than 300 innovators, investors, business leaders and advisers from across the industry, we took the opportunity to share insights and capture the views of professionals on the latest developments impacting our markets.

    With a packed agenda, there was much discussion about the fast-changing macro and geopolitical backdrop, which continues to impact dealmaking. Given the uncertainty, the primary focus of investors today is on top-line growth and late-stage companies that are closer to value generation.

    While in the past there was an almost exclusive appetite for oncology innovations, today investors are hungry for a broader range of advances across infectious diseases, autoimmune disorders and GLP-1 medications used to treat obesity and diabetes.

    Emmanuelle Trombe, partner and co-head of the Firm’s Life Sciences practice, says: “With big pharma facing a patent cliff, acquirers are looking for targets to fill their pipelines and biotech companies are being directed to prioritise identifying breakthrough drugs that will fit those schedules. There is a lot of focus on growth right now.”

    Drug developers were cautioned to remain focused on meeting patient needs first and foremost, however, because big pharma trends can change it is only by demonstrating conviction and maximising value creation that long-term success can be realised.

    In depth

    A Challenging Backdrop

    There are several challenges set to impact life sciences transactions through 2025, with uncertainty about US trade policy and the threat of tariffs shifting both dealmaking and financing dynamics. Acquirers are looking to share risk as well as upside and are keen on more structuring in transactions to bridge valuation gaps.

    We are seeing more creativity in deal structures, whether that involves combining debt and equity financing, embracing partnerships and joint ventures, or including commercial licensing arrangements, royalty financing or take-out optionality in deals. Many venture capital funders in the US are building royalty financing capabilities and are reluctant to take binary risk on investments.

    With the US federal government scaling back staffing at the Food and Drug Administration, boards and investors are expecting delays to drug approvals. That could lead to more clinical trials being conducted in Europe as a means to spread risk, while cuts to US university programmes could further push innovation into Europe.

    It has also become harder for US biotech companies to access capital in 2025, and we may see more partnering deals between US and European companies for late-stage transaction and commercial or distribution deals. There are also signs that US biotech investors are increasingly open to investing in European deals, with a Nasdaq listing no longer a firm requirement.

    European biotechs looking at exit strategies were advised to tap into US capital early by building resources on the ground. Treating investors well to build trust should also be a priority, as well as embracing a four-track strategy by fully preparing for an exit to big pharma, an IPO, an additional round of financing or a licensing deal.

    In a difficult landscape for transactions, the key takeaway for biotechs was that the current market requires a long-term approach: be consistent with drug development in order to build value, pay close attention to the cash runway and build optionality around routes to exit.

    Innovations in Financing

    Financing has been challenging in the biotech space for some time now, with elevated interest rates, geopolitical uncertainty, a tough fundraising environment for venture capital and a difficult capital markets backdrop. The symbiotic relationship between biotech and big pharma means deals are still happening, however, and top performers continue to manage to obtain financing.

    From the lender perspective, higher rates mean better returns so it is a good time for both fundraising and deployment. Debt providers with depth and scale see a good opportunity to provide flexible capital to liquidity-starved businesses. Still, lending in such an uncertain climate brings its own challenges, as do portfolios of companies dealing with their own ups and downs.

    Innovative financing models are driving advancements in health and life sciences, and these advancements, in turn, are reshaping financial strategies. Finance providers are structuring investments with a view to driving value creation for both sides, with co-investments alongside either venture capital or strategic players being embraced as a derisking tool. Often, the struggle is not in finding opportunities to fund, but in building syndicates alongside like-minded investors.

    Finance providers today may be willing to tolerate higher valuations and more financial risk in return for stronger alignment. They are looking for strong management teams and best-in-class technology, with a particular appetite for innovators or managers that can demonstrate the ability to persevere in the face of market challenges.

    Again, biotech companies seeking capital were advised to be creative where access to capital is challenging and work to build trust with financing partners. Many lenders have been willing to provide follow-on capital to businesses facing either equity or cashflow pressures, either by injecting more funding or paying interest in kind for a period, but there are a lot of bespoke financing structures being employed.

    Aymen Mahmoud, partner and head of the European finance practice, says: “The biggest piece of advice we heard for companies was to have a specific plan, anticipate inflection points and ensure they have sufficient runway to get there. Leaders need to be ready to pivot and must demonstrate grit and determination in order to leverage financing opportunities.”

    Authors
    More insights

  • Paint It White: No Sovereign Immunity in Economic Espionage Case

    Paint It White: No Sovereign Immunity in Economic Espionage Case

    ARTICLE

    Paint It White: No Sovereign Immunity in Economic Espionage Case

    May 8, 2025

    Read time: 3 min

    Key takeaways
    Overview
    In depth

    The US Court of Appeals for the Ninth Circuit affirmed a district court’s denial of foreign sovereign immunity to a Chinese company accused of stealing trade secrets related to the production of proprietary metallurgy technology. United States v. Pangang Grp. Co., Ltd., Case No. 22-10058 (9th Cir. Apr. 29, 2025) (Wardlaw, Collins, Bress, JJ.)

    Pangang is a manufacturer of steel, vanadium, and titanium. E.I. du Pont de Nemours (DuPont) had a proprietary chloride-route technology used for producing TiO₂, a valuable white pigment used in paints, plastics, and paper. Pangang allegedly conspired with others to obtain DuPont’s trade secrets related to TiO₂ production through economic espionage in order to use the stolen information to start a titanium production plant in China. The US government filed a criminal lawsuit.

    In defense, Pangang invoked the Foreign Sovereign Immunities Act (FSIA) and federal common law, arguing that it was entitled to foreign sovereign immunity from criminal prosecution in the United States because it was ultimately owned and controlled by the government of the People’s Republic of China (PRC). In a prior appeal, the Ninth Circuit had found that Pangang failed to make a prima facie showing that it fell within the FSIA’s domain of covered entities. On remand, the district court again rejected Pangang’s remaining claims of foreign sovereign immunity, including its claims based on federal common law.

    While the appeal was pending, the Supreme Court’s 2023 decision in Turkiye Halk Bankasi v. United States clarified that common law, not the FSIA, governs whether foreign states and their instrumentalities are entitled to foreign sovereign immunity from criminal prosecution in US courts. This led to a rebriefing of the present appeal to focus on the now-controlling issues concerning the extent to which Pangang enjoys foreign sovereign immunity under federal common law. Under federal common law, an entity must satisfy two conditions to enjoy foreign sovereign immunity from suit:

    • It must be the kind of entity eligible for immunity.
    • Its conduct must fall within the scope of the immunity conferred.

    The Ninth Circuit concluded that Pangang did not make a prima facie showing that it exercised functions comparable to those of an agency of the PRC and therefore was not eligible for foreign sovereign immunity from criminal prosecution. The Court also found that “[t]he mere fact that a foreign state owns and controls a corporation is not sufficient to bring the corporation within the ambit of [sovereign immunity].” Since Pangang’s commercial activities were not governmental functions, there was no evidence that sovereign immunity should be applied. Therefore, the Ninth Circuit affirmed the district court’s denial of the motion to dismiss based on sovereign immunity.

    Authors

    Hannah Hurley

    Associate

    Silicon Valley

    More insights
    Endnotes

  • Quit Monkeying Around: FDA Offers Faster Approval Times in Bid to Phase Out Animal Testing

    Quit Monkeying Around: FDA Offers Faster Approval Times in Bid to Phase Out Animal Testing

    ARTICLE / CLIENT ALERT

    Quit Monkeying Around: FDA Offers Faster Approval Times in Bid to Phase Out Animal Testing

    May 7, 2025

    Read time: 6 min

    Key takeaways
    Overview

    On April 10, 2025, the US Food and Drug Administration (FDA) announced its intent to phase out the use of animal testing in the development of certain drugs and biologics. To help bring this “paradigm shift in drug evaluation” to fruition, FDA is offering pharmaceutical companies incentives such as faster approval times and reduced testing requirements if they leverage emerging technologies that FDA believes hold the promise of cheaper, safer, and more ethical drug development processes. Although FDA’s sights are currently set on obviating the need for animal testing specifically in monoclonal antibody trials, the agency emphasized in the announcement its desire to expand its efforts to all future applicable use cases.

    Background


    For several decades, animal testing has been a foundational part of drug and biologics research and development in the United States. To some industry stakeholders, this approach has proven overly costly and provided only mixed benefit. Critics argue that, beyond the skyrocketing prices to procure lab animals (sometimes tens of thousands of dollars per animal in the case of non-human primates), physiological, biochemical, and behavioral differences between humans and model organisms can generate both false hopes and red flags. Sometimes, serious under-the-radar adverse effects are not detected until human trials take place. Many advocacy groups raise moral and ethical concerns related to pain and other harms inflicted by arguably avoidable animal testing.

    Until recently, sponsors were required under the Federal Food, Drug, and Cosmetic Act of 1938 to test all products on animals as a safety measure prior to testing them on humans. In September 2022, Congress passed the FDA Modernization Act 2.0, which removed the requirement that sponsors engage in animal testing to support an investigational new drug application (IND), instead allowing them to generate and provide supportive data through various other means. In February 2024, Congress introduced the FDA Modernization Act 3.0, which was meant to push FDA to implement the earlier statute. A bipartisan group in the Senate reintroduced Act 3.0 in January 2025 shortly after the change in administration. Many modern policymakers have welcomed innovative technologies discussed further below as offering better alternatives to animal research.

    In depth

    In the April 10, 2025, announcement, FDA Commissioner Marty A. Makary, MD, laid out an ambitious three-year roadmap “to make animal studies the exception rather than the norm for pre-clinical safety [and] toxicity testing.”

    At the center of FDA’s roadmap are certain “new approach methodologies” (NAMs) that would underpin such a transition. These NAMs include machine-learning and artificial intelligence (AI) predictive models, which can be used to analyze a drug or biologic’s active ingredients and structure and foresee potential adverse-event-causing toxicities. These may also be used to assess whether a compound could affect a part of the body that is not actively targeted. The roadmap also references “organs-on-chips,” where organoids produced from human cells are integrated with a bioengineered chip to create a controlled environment simulating that of the human body.

    To facilitate the industry’s adoption of these NAMs, FDA plans to take a multifaceted policy approach that focuses on breaking down barriers to uptake and providing direct incentives for the industry. As one example of its barrier-breaking approach, FDA stated its intent to construct a large public database of toxicological data to allow machine-learning models to be more effectively trained. Such a database would be constructed in concert with other federal health agencies, such as the National Institutes of Health, and would leverage pre-existing international safety and toxicity data. To that end, FDA also announced its intent to waive the requirement that sponsors collect additional human data where the product has been approved in a foreign country with similar regulatory standards.

    FDA’s roadmap also includes direct incentives, including faster approval times and reduced testing requirements, to encourage sponsors to use NAMs as part of their data-gathering methods. For example, the agency mentioned it hopes to encourage NAM adoption by fast-tracking regulator meetings and product reviews for INDs that use NAMs. FDA stated that it could reduce or altogether waive animal testing requirements in certain cases, such as where short-term animal testing raised no red flags and NAM trials are ongoing.

    While the FDA roadmap primarily focuses on policy initiatives to encourage the industry’s move to NAMs, it also recognizes that key technical advancements and knowledge-building activities are required to ensure a smooth transition. In concert with its industry-focused initiatives, FDA intends to engage in measures such as gap analyses to determine where NAMs are best suited to replace or augment animal data. The agency also looks to invest in the development of NAMs by studying their costs and benefits in the preclinical context.

    Through this synergistic approach, Commissioner Makary hopes to realize a “win-win for public health efforts” whereby the development of life-saving treatments is accelerated while animal testing is gradually phased out.

    Next Steps


    To implement the initiatives described in its roadmap, FDA plans to update existing guidance and issue new guidance clarifying its vision for the appropriate use of NAMs in drug and biologics development. FDA also plans to host a public workshop later this year to discuss the roadmap and aims to launch a pilot program allowing select monoclonal antibody developers to use a primarily non-animal-based testing strategy under close FDA consultation.

    McDermott will continue to monitor any changes FDA makes to facilitate the adoption of NAMs in preclinical testing and analysis. If you have questions about how FDA’s roadmap could impact your business, please contact a member of McDermott’s Food, Drug & Medical Device Regulatory Group.

    Authors

    James R. Ravitz

    Partner

    Washington, DC

    Paul S. Gadiock

    Partner

    San Francisco

    Jeff Weinstein

    Counsel

    Washington, DC

    Marissa Hill Daley

    Law Clerk

    Washington, DC

    Henry Fisher

    Associate

    Washington, DC

    More insights

  • Economic Ownership of Shares Transferred as Collateral

    Economic Ownership of Shares Transferred as Collateral

    ARTICLE / CLIENT ALERT

    Economic Ownership of Shares Transferred as Collateral

    April 28, 2025

    Read time: 7 min

    Key takeaways
    Overview

    Dividends from shares are taxable for shareholders, even if the dividends do not remain with them economically.

    This (not entirely new) finding can be gleaned from a recent Federal Fiscal Court (BFH) ruling in which the BFH specified who is considered a shareholder: The person who objectively and in fact is entitled to the essential rights of the share. In contrast, subjective intentions are irrelevant, so it is irrelevant whether the shareholder wishes to exercise their voting rights at general meetings.

    In depth

    Background: Shareholders Pay Tax on Dividends Depending on Their Investor Category

    Dividends are taxed by the “shareholder” of shares (Section 20(5) of the German Income Tax Act (EStG)). This is usually the civil law owner, who is also the beneficial owner. However, if the beneficial owner (Section 39(2) No. 1 of the German Fiscal Code (AO)) differs from the civil law owner, the beneficial owner is the shareholder. The beneficial owner is the person who is entitled to the essential administrative and property rights associated with the share (particularly the right to receive dividends and the right to vote) and who can therefore exclude the civil law owner from the economic use of the share.

    The taxation of dividends for shareholders depends on their investor category. The following generally applies:

    • Private investors pay withholding tax at a rate of 25%.
    • Natural persons who hold shares as business assets pay tax on dividends under the partial income procedure. Dividends are 40% tax-free and subject to the individual income tax rate of up to 45%, which in many cases results in a similar tax burden to that of private investors.
    • (Domestic) legal entities and other investors subject to a corporate income tax receive 95% of dividends tax-free (Section 8b of the German Corporation Tax Act (KStG)), provided these are not smaller investors (a threshold of 10% for corporate income tax and 15% for trade tax).

    The distributing public limited company must withhold a 25% withholding tax in all cases. While this generally has a final effect for private investors, in the other two cases the withholding tax is offset against the income tax or corporate income tax liability.

    What Did the BFH Decide?

    In its judgment, the BFH considered the civil law owner of shares to be the tax shareholder, as well as the beneficial owner. For a deviating beneficial ownership, it was not sufficient that the civil law owner passed on the dividends received from the shares in full and did not retain any income from the shares.

    Circumstances of the Case

    In the case in dispute, the plaintiff (a public limited company) transferred fixed-interest securities to its bank by way of a loan. As security, the plaintiff received shares from the bank’s portfolio, which were selected by employees of the plaintiff in such a way that the plaintiff was the owner of the shares on the dividend date. The shares were then exchanged for shares for which the dividend date was still pending. The plaintiff had unrestricted power of disposal over the shares transferred as collateral and could exercise the voting rights attached to them but did not do so and did not intend to do so. Upon termination of the securities loans, had to transfer back shares of the same type and quantity. The plaintiff also had to pass on dividends received to the bank at the same time and in the same amount and pay an “arrangement fee” of 2.2% of the dividends to the bank.

    Determining the Tax Shareholder

    In the taxation and subsequent court proceedings, there was disagreement as to who was the shareholder of the transferred shares as collateral and what tax consequences would be drawn from the transaction.

    The plaintiff wanted 95% of the dividends to be treated as exempt from corporate income and trade tax (in the disputed year 2006 as the above mentioned full tax liability on dividends from shares below 10% and 15% respectively did not yet apply) and the payments to the bank (forwarding dividends and payment of arrangement fees) to be treated as tax-deductible operating expenses. This would result in a tax advantage for the plaintiff.

    The tax office did not want to recognise this tax advantage because it considered the transactions as a whole to be an abuse of tax planning schemes (Section 42 of the AO).

    The Munich Fiscal Court dismissed the action because it considered the bank to be the economic owner (the tax shareholder) to whom the shares were attributable because the bank received the dividends economically. However, the parties had not intended for the shares to be used or the economic opportunities and risks to be transferred to the plaintiff. The dividends and their transfer were only transitory items. The plaintiff had neither received tax-free dividends nor incurred tax-deductible operating expenses.

    BFH: A Shareholder Is Someone Who Can Exercise the Rights associated With the Shares

    The BFH considered the plaintiff to be the shareholder. This is because it is irrelevant for the determination of the shareholder whether the civil law owner or economic owner subjectively intends to exercise the rights associated with the shares. Instead, it must be asked whether the civil law owner has the legal powers and whether they can actually exercise them. This was the case with the plaintiff, who, as the civil law owner of the shares, was also entitled to sell them or exercise their voting rights at general meetings, for example.

    Whether there was an abuse of tax planning schemes under Section 42 of the AO (as the tax office believes) must now be clarified by the Munich Fiscal Court in the second instance, to which the BFH referred the case back. The Munich Fiscal Court now has to find whether the plaintiff and the bank can prove that the transactions also had a purpose other than achieving the tax advantage described.

    Outlook for Practice on the Correct Determination of the Shareholder

    The BFH’s ruling will be referred to even more frequently when it comes to determining shareholders, primarily for the following three reasons:

    1. A shareholder can also be someone who is obliged to forward any dividend income.
    2. A shareholder only must be able to exercise the rights attached to the share. They do not have to actually exercise them or have such intentions. The BFH thus confirms its ruling issued on 29 September 2021 (Ref.: I R 40/17). To correctly determine the shareholder, particular attention must be on which rights the shareholder can objectively exercise, even if they may subjectively have other plans. According to the BFH, the Munich Fiscal Court had wrongly examined what the plaintiff intended to do with the shares and not what rights they actually had.
    3. The BFH held that the designation of the share transfer as a security (regardless of the wording of Section 39(2) No. 1 sentence 2 of the AO) does not lead to the shares being attributed to the security provider (the bank) because, unlike in typical cases of security ownership, the plaintiff was entitled to sell the shares even if a default event did not occur.

    Whether the specific tax structure constitutes an abuse of tax planning schemes within the meaning of Section 42 of the AO is to be clarified by the Munich Fiscal Court in the second instance. However, under current law, the disputed tax advantage could no longer be achieved through the specific arrangement because dividends from smaller shares are taxable (Section 8b(4) of the KStG) and the transfer of dividends would no longer be a deductible operating expense (Section 8b(10) of the KStG).

    Authors

    Andreas Klaus, LL.M.

    Associate

    Munich

    Jonathan Storz

    Counsel

    Munich

    More insights

  • The New UK Procurement Regime and the Economic Crime & Corporate Transparency Act: Heightened Exclusion & Debarment Risks

    The New UK Procurement Regime and the Economic Crime & Corporate Transparency Act: Heightened Exclusion & Debarment Risks

    ARTICLE

    The New UK Procurement Regime and the Economic Crime & Corporate Transparency Act: Heightened Exclusion & Debarment Risks

    May 8, 2025

    Read time: 19 min

    Overview
    • The UK Procurement Act 2023 (the Procurement Act) came into force on 24 February 2025. It introduced significant changes to the UK public procurement landscape including a new regime for suppliers to be excluded from a procurement process by the relevant contracting authority and placed on a central debarment list for up to five years.
    • The overhaul of corporate criminal liability under the UK Economic Crime & Corporate Transparency Act 2023 (ECCTA) makes it much easier for UK authorities to prosecute corporate wrongdoing. Prosecution may trigger mandatory or discretionary sanctions under the Procurement Act.
    • The interplay between ECCTA and the Procurement Act means that companies relying on UK public contracts (e.g., those in the defence, healthcare, transport or utilities sectors) face materially expanded risks. Given the potentially catastrophic consequences of exclusion and debarment, it is even more important that affected companies take steps now to mitigate the risks posed by ECCTA. Key provisions of ECCTA come into force on 1 September 2025; others have been in force since 26 December 2023.
    • This alert highlights the key risks and explains what companies need to do now. For further detail on compliance with ECCTA, see our previous alert The UK Economic Crime & Corporate Transparency Act: What companies need to know and what they can do to prepare.[1]
    In depth

    The Old UK Procurement Regime

    The previous UK procurement regime was made up of a patchwork of regulations,[2] all of which have been replaced by the Procurement Act.

    Broadly, under the old regime, mandatory exclusion was triggered by a conviction for any specified offence including bribery (pursuant to sections 1, 2 or 6 of the UK Bribery Act 2010 (UKBA) or under the pre-UKBA laws) and certain fraud, money laundering and tax offences.[3]

    Discretionary grounds for exclusion included a company being “guilty of grave professional misconduct, which renders its integrity questionable…”[4] It was generally understood that a conviction for the corporate offence of failing to prevent bribery (s.7 UKBA) was capable, in principle, of meeting this test. For example, the judgment approving the 2020 Airbus Deferred Prosecution Agreement (DPA) acknowledged that a conviction for the s.7 UKBA offence could result in discretionary exclusion.[5]

    Further, as this discretionary ground did not hinge on a criminal conviction, the facts giving rise to a non-prosecution outcome such as a DPA could, depending on their nature, amount to sufficiently grave misconduct.

    This was illustrated by the 2019 DPA between the Serious Fraud Office (SFO) and Serco Geografix Limited (SGL) in respect of certain fraud offences relating to contracts with the UK Ministry of Justice (MoJ). The judgment approving the DPA stated that “[t]he facts giving rise to the DPA must amount to such misconduct”[6] but the exercise of the discretion was entirely a matter for the UK government.[7] The government determined not to exclude SGL or its parent companies because it was satisfied with the extent of the company’s ‘self-cleaning’[8] measures.[9]

    The issue received effectively the same consideration in the judgment approving the 2020 DPA between the SFO and G4S Care and Justice Services (UK) Limited.[10]

    The Procurement Act

    Overview

    As with the old regime, companies risk exclusion from public procurement processes based on both mandatory and discretionary grounds. Subject to certain changes, the grounds remain substantially the same.

    However, the Procurement Act also introduces an entirely new debarment list managed by central government. Following exclusion by a contracting authority (on mandatory or discretionary grounds) and a subsequent investigation, a Minister can place a company on the debarment list, excluding them from all public contracting, for up to five years.

    Mandatory Exclusion Grounds

    The mandatory exclusion grounds are set out in Schedule 6 of the Procurement Act.[11] These include a conviction for various specified offences, typically within the last five years.[12] The list includes many of the offences whereby, due to ECCTA, corporate liability can now be triggered by the conduct of a company’s ‘senior managers’ (the Senior Manager Regime). This regime came into force on 26 December 2023.

    For the purpose of the Senior Manager Regime, a ‘senior manager’ is any individual that plays a significant role in: (i) the making of decisions about how the whole, or a substantial part of, the company’s activities are to be managed or organised; or (ii) the actual managing or organising of the whole, or a substantial part of, the company’s activities.

    The test is one of fact based on all the circumstances. Government guidance published in November 2024 (the ECCTA Guidance)[13] confirmed that senior individuals within non-executive and non-client facing roles could satisfy the definition (e.g. persons in Legal, Compliance, Finance, Sales, Marketing and Human Resources). Accordingly, this is potentially a very broad group indeed.

    The offences which overlap the Senior Manager Regime and Schedule 6 of the Procurement Act include:[14]

    • sections 1, 2 and 6 of the UKBA
    • sections 2, 3, 4, 6 or 7 of the Fraud Act 2006
    • sections 327-329 of the Proceeds of Crime Act 2002
    • false accounting and related offences under the Theft Act 1968
    • conspiracy to defraud
    • cheating the public revenue and various statutory tax offences

    The previous procurement regime had similar consequences for companies convicted of these offences. However, before ECCTA, establishing corporate criminal liability was generally very difficult due to the ‘identification principle’ in English law whereby only the conduct of a company’s ‘directing mind and will’ (DMW) could be imputed to the company. The narrow scope of the DMW meant that a prosecutor effectively had to prove that the board (or individuals with specific authority delegated to them by the board) were involved in the relevant crime. This led to difficulties prosecuting companies, as evidence implicating such individuals was generally hard to find, or it was generally more junior employees who engaged in the relevant conduct. Importantly, the Senior Manager Regime has replaced the DMW requirement for the offences listed above and captures a much broader range of individuals.  This means that a major obstacle to convictions for mandatory exclusion offences has now been removed.

    Importantly, the mandatory exclusion grounds under the Procurement Act also extend to any “connected person” or “associated person” of the supplier. In the context of the Procurement Act, that includes:

    • “connected person” – parent and subsidiary companies, any person (legal or natural) who exercises, or has the right to exercise, significant control or influence over the supplier, and any person (legal or natural) over whom the supplier exercises, or has the right to exercise, significant influence or control.[15]
    • “associated person” – anyone the supplier is relying on in order to satisfy the conditions of participation[16] (other than a guarantor),[17] such as consortium partners and sub-contractors.[18]

    This combines with the Senior Manager Regime to expansive effect. The implication is that the mandatory debarment of a supplier may be triggered not only by the actions of any of their own senior managers, but also the senior managers of any company that, for Procurement Act purposes, is a “connected person” or “associated person” of the supplier. This potentially casts an extremely wide net.

    Discretionary Exclusion Grounds

    The discretionary exclusion grounds are set out in Schedule 7 of the Procurement Act. These include where the contracting authority “considers that the supplier or a connected person has engaged in professional misconduct which brings into question the supplier’s integrity” or where a court, regulator or other authority has ruled to the same effect. Again, this extends to any “associated person” of the supplier for the purposes of the Procurement Act.

    Consistent with the equivalent provision under the old regime (as discussed above), a conviction for failing to prevent bribery (s.7 UKBA), or a DPA in respect of, e.g., bribery or fraud offences, all appear capable of triggering this.

    As regards ECCTA, the ‘failure to prevent fraud’ offence (s.199 ECCTA) comes into force on 1 September 2025. In essence, a company commits this offence where one of its ‘associates’ (including its employees, agents, subsidiaries and anyone who performs services for it or on its behalf) commits a specified fraud offence intending to benefit the company. The only defence is for the company to prove that it had reasonable fraud prevention procedures in place.

    The question therefore arises as to how a conviction for this new offence, or a DPA in respect of the same, would be considered under the Procurement Act.

    Helpfully in this respect, “professional misconduct” is defined in Schedule 7 of the Procurement Act as conduct involving dishonesty, impropriety, or a serious breach of applicable ethical or professional standards. The fraud offences specified in ECCTA for the purpose of the failure to prevent offence all require an element of dishonesty.[19] However, that dishonesty would be on the part of the associate. The question for the purpose of the discretionary exclusion ground is whether the company (or a “connected person” or an “associated person”)[20] engaged in dishonest or improper conduct, etc.

    In some scenarios, the associate whose fraudulent conduct the company failed to prevent will also be a “connected person” or “associated person” (as defined in the Procurement Act), thereby falling within the discretionary ground for exclusion. However, this will not necessarily be the case. The analysis will always hinge on the precise nature of the associate’s role. Where the associate is not a “connected person” or an “associated person” (as defined in the Procurement Act), the relevant professional misconduct would need to be on the part of the company itself.

    In some circumstances, a company convicted of failing to prevent fraud may not have engaged in dishonest or improper conduct – the offence can be committed without the knowledge or involvement of the company in the underlying fraud. Ultimately, much will turn on the particular facts in each case, including, for example, the degree of culpability of the board and/or senior management.[21]

    Additional Test (Self-Cleaning)

    Where a mandatory or discretionary exclusion ground does apply, the contracting authority must also be satisfied that the circumstances giving rise to its application are “continuing or likely to occur again”.[22] This test effectively replaces the self-cleaning mechanism under the old regime. A non-exhaustive list of factors that may be considered include:[23]

    • evidence that the company has “taken the circumstances seriously”, such as by paying compensation;
    • taking steps to prevent the circumstances continuing or reoccurring, such as by changing personnel or implementing procedures and training;
    • allowing the monitoring or verification of such steps; and
    • the time since the circumstances last occurred.

    A company can make representations and provide evidence in relation to the above (and any other relevant factors).

    Government guidance on the Procurement Act (Procurement Act Guidance) states that, in this context, the circumstances giving rise to the application of the exclusion ground include the “underlying issues” as well as the specific misconduct. The Procurement Act Guidance gives the examples of a “a toxic office culture, due diligence failures, a lack of a compliance function or inappropriate governance mechanisms.”[24]

    A company that has previously resolved wrongdoing through a DPA (whether for substantive offences or failure to prevent offences), and subsequently complied with its terms, may have a strong chance of arguing that the underlying circumstances are not continuing or likely to reoccur.

    For a DPA to have been approved, the prosecutor and the court must have been satisfied that it was in the public interest. Had they considered the circumstances to be continuing or likely to reoccur, there would – almost by definition – have been no DPA. DPAs also invariably involve the payment of a financial penalty, a recognition that the company has taken matters seriously (e.g., through cooperating and, potentially, self-reporting) and substantial compliance remediation. Indeed, the Procurement Act Guidance expressly states that contracting authorities should take into account “the level and nature of cooperation” with the appropriate authorities in determining whether a company has taken matters seriously.[25] The factors in the DPA Code of Practice tending against prosecution also broadly map against the relevant criteria, including, for example, that the company “in its current form is effectively a different entity from that which committed the offences…”[26]

    On 24 April 2025, the SFO published new guidance stating that if a company promptly self-reports suspected corporate criminal conduct and co-operates fully it can expect to be invited into DPA negotiations “unless exceptional circumstances apply”.[27] Given the potential importance of a DPA in helping to satisfy the self-cleaning test – and thereby avoiding exclusion and debarment – this may prove to be an attractive incentive to relevant companies.

    On the other hand, a company convicted of an offence (i.e., where a DPA was not in the public interest) may well still have arguments to make in relation to self-cleaning, given the fact-specific nature of the evaluation, albeit from a less advantageous starting point compared to a DPA.

    Debarment List and Investigations

    The Procurement Act introduces a new, centralised debarment list. The process is triggered by a contracting authority notifying central government that it has excluded a supplier from a given process.[28] Following an investigation, a decision will be taken on whether to add the supplier to the debarment list.[29]

    Suppliers must be notified of an investigation and given an opportunity to make representations. The government also has extensive powers to require the supplier (and their “connected persons”) to provide any documents and/or other assistance it may reasonably require.[30] Although there is no duty to cooperate, serious non-compliance may itself constitute a mandatory ground for exclusion.[31]

    Once concluded, the government must provide to the supplier, and publish, an investigation report.[32] The report must give reasons why any mandatory or discretionary grounds are considered to apply (including the self-cleaning assessment discussed above) and whether an entry will be made on the debarment list.[33]

    Where a supplier is to be added to the list, they must be provided with a decision notice, triggering: (i) an 8 day standstill period during which the supplier may apply to court for interim relief;[34] and (ii) a 30 day period during which they may appeal the debarment decision – but only where it believes there has been a material mistake of law.[35] Additionally, suppliers may apply to the government at any time for their removal. The government need only consider such applications where there has been a material change in circumstances, or the supplier provides significant new information.[36]

    Take-Aways in Relation to ECCTA

    The interplay between ECCTA and the Procurement Act has the potential to trigger a chain of events with extremely serious consequences.

    Prior to ECCTA, it was generally very difficult to establish corporate criminal liability in the UK. The range of circumstances in which a company could have been successfully prosecuted for an offence carrying mandatory exclusion was correspondingly narrow. The Senior Manager Regime has removed that obstacle and significantly widened the net for many such offences (e.g., bribery, fraud, false accounting, money laundering, tax evasion).

    Combined with the Procurement Act, this means that the conduct of a single senior manager of (i) the company, (ii) its “connected persons”, or (iii) its “associated persons”[37] is potentially sufficient to trigger exclusion from a specific procurement process and, thereafter, an investigation leading to a place on the central debarment list and debarment from all public contracts.

    All of the above may play out in public, leading to contagion risk under the applicable exclusion/debarment regimes of other countries and/or any relevant multilateral development banks.

    Likewise, from 1 September 2025, the new failure to prevent fraud offence (s.199 ECCTA) means that the actions of all a company’s ‘associates’ (i.e., employees, agents, subsidiaries and anyone else providing services for it or on its behalf) will be capable of triggering discretionary exclusion and debarment.

    Conclusion

    The combined impact of ECCTA and the Procurement Act means that companies relying on UK public contracts face a materially expanded risk universe. To avoid the potentially catastrophic consequences of exclusion and debarment, such companies have an even greater imperative to implement the steps detailed in our previous alert.[38] In summary, key aspects include:

    Senior Manager Regime:

    • Identifying all potential ‘senior managers’ (according to the definition in ECCTA), across all functions and wherever located. This exercise should factor in succession planning and be refreshed periodically and following reorganisations.
    • Rolling out tailored, enhanced compliance training to the key population(s) identified.
    • Drafting or refreshing policies and procedures relating to the relevant offences.[39]

    Failure to Prevent Fraud:

    • A vital starting point is to undertake a detailed fraud risk assessment to determine the risk profile across the business.
    • The methodology for conducting a safe and reliable risk assessment is crucial to avoid certain common pitfalls, including around privilege risk. Our previous alert provides further information in this respect.
    • Based on the fraud risk assessment, companies will need to design and implement proportionate policies and procedures to help ensure that the ‘reasonable procedures’ defence is available. The approach should be informed by the six key principles underpinning the official ECCTA Guidance.[40]

    Notably, the components of ‘reasonable procedures’ may substantially overlap with the representations a company would make if it was seeking to demonstrate that it had effectively self-cleaned. For example, a company may point towards a genuine culture of compliance,[41] and supply chain due diligence and monitoring procedures, as evidence that the circumstances giving rise to a mandatory or discretionary exclusion ground will not reoccur. This added value further strengthens the investment case for taking pro-active steps now.

    McDermott’s Investigations & Compliance team has decades of experience helping multinational organisations navigate the UK’s increasingly challenging compliance environment, has advised on the design and implementation of compliance procedures, and has acted on some of the highest profile corporate investigations and resolutions in recent years.

    Please contact us if you wish to discuss any of the issues in this note.

    Tabs

    Simon Airey

    Partner

    London – 22 Bishopsgate

    Andrew Butel

    Counsel

    London – 22 Bishopsgate

    More insights
    Endnotes

    [1] The UK Economic Crime & Corporate Transparency Act 2023

    [2] The Public Contracts Regulations 2015 (PCR 2015), the Utilities Contracts Regulations 2016 (UCR 2016), the Defence and Security Public Contracts Regulations 2011 (DSPCR 2011) and the Concession Contracts Regulations 2016 (CCR 2016).

    [3] The grounds for mandatory and discretionary exclusion were specified in Reg. 57(1) of the PCR 2015, Reg. 80(1) of the UCR 2016, Reg. 23(1) of the DSPCR 2011, and Reg. 38(8) of the CCR 2016.

    [4] Reg. 57(8)(c) of the PCR 2015. The same ground featured in the UCR 2016 (Reg. 80(1)) and CCR 2016 (Reg. 38(16)). The DSPCR 2011 included similar wording.

    [5] SFO v Airbus SE [2020] at [84]

    [6] SFO v Serco Geografix Limited [2019] at [29]

    [7] Ibid., at [30]

    [8] A mechanism by which a company could seek to convince the contracting authority that it had taken appropriate remedial measures that were “sufficient to demonstrate its reliability” despite the existence of mandatory or discretionary grounds for exclusion (Reg. 57(13)-(17) of the PCR 2015).

    [9] SFO v Serco Geografix Limited [2019] at [30]

    [10] SFO v G4S Care and Justice Services (UK) Limited [2020] at [31-33]. The case related to fraud under similar MoJ contracts as the SGL DPA.

    [11] Per s.57(6)

    [12] Schedule 6, paragraph 44(1)

    [13] Economic Crime and Corporate Transparency Act 2023: Guidance to organisations on the offence of failure to prevent fraud (November 2024)).

    [14] Ancillary offences (e.g., attempting, conspiring, aiding, and abetting) also fall within Schedule 6 of the Procurement Act and the ambit of the Senior Manager Regime.

    [15] Per Schedule 6, paragraph 46. It also includes directors.

    [16] Conditions a contracting authority may set to ensure that suppliers have the legal and financial, or technical, or ability to perform the contract (s. 22).

    [17] s.26(4)

    [18] s.22(8)-(9)

    [19] Schedule 13 ECCTA

    [20] Per the Procurement Act definition

    [21] Logically, the same analysis would apply to a DPA in respect of the failure to prevent fraud offence (s. 199 ECCTA), and a conviction or DPA for failing to prevent bribery (s. 7 UKBA).

    [22] s.57(1)(a)(ii) and 57(2)(a)(ii)

    [23] s.58(1)

    [24] See Guidance: Exclusions, paragraph 54

    [25] Ibid., paragraph 57

    [26] DPA Code of Practice, paragraph 2.8.2.v.

    [27]SFO External Guidance on Corporate Co-Operation and Enforcement in relation to Corporate Criminal Offending (24 April 2025) at https://www.gov.uk/government/publications/sfo-corporate-guidance/sfo-corporate-guidance

    [28] s.59

    [29] s.60

    [30] s.60(6)

    [31] s.60(7) / s.43

    [32] s.6(3). There are certain limited exceptions to the transparency and publication requirements, including for national security purposes.

    [33] s.61(4)

    [34] s.63

    [35] s.65

    [36] s.64

    [37] As defined in the Procurement Act

    [38] The UK Economic Crime & Corporate Transparency Act 2023

    [39] There is no ‘reasonable procedures’ defence (unlike with the failure to prevent fraud offence). However, such procedures are vital to mitigate the risks of wrongdoing in the first place.

    [40] Risk assessment; proportionate procedures; top level (board) commitment; communication and training; due diligence; and monitoring and review.

    [41] Demonstrated, for example, by board-level commitment, a well-resourced compliance function and employees empowered to ‘speak up’.


  • California Amends AB 1415, Bill That Expands OHCA’s Healthcare Transaction Review Authority

    California Amends AB 1415, Bill That Expands OHCA’s Healthcare Transaction Review Authority

    ARTICLE / CLIENT ALERT

    California Amends AB 1415, Bill That Expands OHCA’s Healthcare Transaction Review Authority

    May 2, 2025

    Read time: 5 min

    Key takeaways
    Overview

    The California Assembly amended Assembly Bill (AB) 1415 on April 24, 2025. The bill aims to bring healthcare investments by private equity groups and hedge funds more fully into the scope of the California Office of Health Care Affordability (OHCA) transaction review process. The amended bill notably removes management services organizations (MSOs) and parent entities from the definition of “health care entity,” but retains reporting obligations for those entities if they enter into a transaction with another health care entity. The amended bill would also allow OHCA to impose data reporting requirements on MSOs.

    Stakeholders should continue to monitor the progress of AB 1415 and its potential impact on the OHCA transaction review process. If signed into law, AB 1415 would likely take effect on January 1, 2026.

    In depth

    Our prior On the Subject summarized the proposed changes to the OHCA transaction review process in the version of AB 1415 that was introduced on February 21, 2025. The amended bill includes the following material changes:

    • Removes MSOs and Parent Entities From “Health Care Entity” Definition
      AB 1415 originally included MSOs and parent entities of providers as types of “health care entities.” The amended version removes both MSOs and parent entities from the definition of health care entity and adds them to the newly defined term “noticing entity,” which refers to entities that have an obligation to report certain material transactions between themselves and a health care entity. “Noticing entity” also includes private equity groups, hedge funds, and entities created for the purposes of entering into agreements or transactions with health care entities.
    • MSO Monitoring
      The amended bill states that OHCA will establish MSO data reporting requirements “as necessary to carry out the functions of the office” and adds MSOs to an existing list of entities that OHCA will research and evaluate to determine whether the current OHCA transaction review process captures all entities that “significantly affect health care cost, quality, equity, and workforce stability.”
    • Health System Definition
      The amended bill broadens the new definition of “health system” to include a combination of one or more hospitals and one or more providers, rather than a combination of one or more hospitals and one or more physician organizations. The definition also includes a combination of one or more providers, rather than a combination of one or more physician organizations.

    Key Takeaways

    • MSO Acquisitions: Under the amended bill, MSOs would no longer fall within the definition of health care entity, which critically impacts the applicability of the OHCA transaction review requirements to changes of ownership or control of an MSO. Under the initial version of AB 1415, if a buyer acquired equity in an MSO in California, the transaction would potentially be reportable to OHCA because there would be a change in control of a health care entity. Under the amended bill, an MSO sale is unlikely to be reportable, as long as no assets or control of another health care entity are transferred.
    • Parent Entities: The removal of certain parent entities (“an entity that owns, operates, or controls a provider, regardless of whether the provider is currently operating, providing health care services, or has a pending or suspended license”) from the definition of health care entity would narrow the types of transactions potentially subject to OHCA’s reporting requirements. However, such entities would still have an obligation to report to OHCA if they enter into a material transaction with a health care entity.
    • MSO Data Reporting: While the amended bill removes MSOs from the definition of health care entity, it allows OHCA to develop data reporting requirements for MSOs. While the language of the bill is silent as to the nature of these reporting requirements, OHCA likely would want to better understand the relationships between MSOs and other health care entities.
    • Private Equity Group and Hedge Fund Reporting Requirement: No material changes were made to the language requiring private equity groups and hedge funds (and their downstream affiliates) to report certain transactions if the counterparty in a transaction is a health care entity. AB 1415 would specifically require the private equity group or hedge fund to submit notice to OHCA, which would involve the submission of a substantial amount of information regarding the private equity group or hedge fund, including financial statements, organizational charts, and information regarding past healthcare transactions consummated by the private equity group or hedge fund.
    Authors

    Travis Jackson

    Partner

    Los Angeles

    Cathy Ren

    Partner

    Los Angeles

    Matthew David

    Associate

    Los Angeles

    More insights

  • Antitrust Under Trump: May 2025 Updates

    Antitrust Under Trump: May 2025 Updates

    ARTICLE / CLIENT ALERT / US POLICY

    Antitrust Under Trump: May 2025 Updates

    May 2, 2025

    Read time: 6 min

    Key takeaways
    Overview

    As the Trump administration’s antitrust landscape continues to develop, companies should stay alert to key changes in merger filing requirements, remedy expectations, agency personnel, and more. The Federal Trade Commission (FTC) is under pressure as Congress is considering merging its competition mandate into the US Department of Justice (DOJ). Meanwhile, the fired FTC commissioners continue to fight for reinstatement. Signs indicate that the agencies plan to streamline the merger review process, and that the new administration will prioritize deregulation of American business to promote small business, manufacturing, and agriculture.

    Below is a high-level review of recent developments that could impact business strategy, dealmaking, and compliance.

    In depth

    US House Panel Considering One Agency Act to Eliminate FTC Competition Authority

    • A Republican-sponsored bill seeking to consolidate agency antitrust powers, the One Agency Act, was scheduled to be marked up by the US House Judiciary Committee.
    • The bill would allow the antitrust agencies one year to implement the transition, wherein the FTC will transfer its antitrust functions, employees, assets, and funding to the DOJ’s Antitrust Division.
    • The bill also allocates funding for the consolidation of the two agencies, and it grants the DOJ the power to require businesses to file annual or special reports – or answers in writing to specific questions – about their organization, practices, management, and relationships with other businesses. This new power mirrors the FTC’s ability to conduct industry studies to better understand competition in those industries.

    Commissioner Holyoak Wants More Early Termination Requests

    • To achieve a friendlier merger review process and create a more predictable antitrust environment through the granting of early termination, FTC Commissioner Melissa Holyoak reminded parties at a University of California, Berkeley, forum that the FTC will grant early termination requests where possible.
    • Concerned that merging parties might be “gun-shy” about submitting for early termination, Holyoak explained that the requests will help reduce the workload of FTC staff and help parties close transactions sooner.

    The Continuing Saga of the Fired FTC Commissioners

    Democratic Attorneys General Support Terminated FTC Commissioners

    • As we reported earlier, FTC Commissioners Rebecca Slaughter and Alvaro Bedoya filed a lawsuit against President Trump and the remaining FTC commissioners, claiming that their termination was unlawful because Supreme Court precedent from 1935 in Humphrey’s Executor protects FTC commissioners from removal by the president for political reasons.
    • Attorneys general from 20 states as well as the District of Columbia have filed a joint amicus brief in support of former FTC Commissioners Slaughter and Bedoya.
    • The amicus brief argues that President Trump’s termination of Slaughter and Bedoya violates long-standing federal law preventing the removal of FTC commissioners by the executive office for reasons other than inefficiency, neglect of duty, or malfeasance in office.
    • The brief went on to argue that the FTC was deliberately established by Congress as an independent and bipartisan body, and that the FTC’s bipartisan nature is a vital part of its success.

    Trump, Remaining FTC Commissioners Argue to Uphold Termination of Former Commissioners Slaughter and Bedoya

    • In response to Bedoya and Slaughter’s motion for expedited summary judgment, Trump and Commissioners Ferguson, Holyoak, and Meador filed a brief arguing that the more recent Supreme Court opinion in Seila Law made Humphrey’s Executor removal restrictions unconstitutional because Congress may not restrict the president’s power to remove officers of agencies exercising executive power.
    • In their brief, Trump and the commissioners argued that the FTC today exercises substantial executive power – such as the ability to seek injunctions, conduct investigations, and impose monetary penalties – that the FTC in 1935 did not exercise because its authority was limited to preparing reports and recommendations on unfair competition for Congress and the judiciary.
    • They also argued that Slaughter and Bedoya’s seeking of reinstatement rather than backpay is unwarranted and that the president should not be forced to retain officers performing executive functions that he no longer believes should wield that power
    • Twenty-one other states have filed papers arguing in support of Trump’s authority to dismiss the commissioners, including the Arizona State Legislature, despite the Arizona attorney general joining the amicus brief against the terminations.

    FTC Offering Staff Deferred Resignation Program

    • The Office of Personnel Management has granted the FTC the ability to offer buyouts to eligible FTC employees through the Voluntary Early Retirements or Voluntary Separation Incentive Payments programs.

    Chair Ferguson Objects to Comparison to Lina Khan

    • In an editorial, The Wall Street Journal editorial board compared FTC Chair Andrew N. Ferguson to former Chair Lina Khan, pointing to the new administration’s support of continued antitrust regulation of American business. Ferguson vigorously disagreed with the comparison.
    • Ferguson, speaking at the Semafor World Economy Summit, explained that though he, like Khan, believes in strong antitrust enforcement where he thinks a merger is anticompetitive and he can prove it in court, he distinguished himself by saying that if those things are not true, he will get out of the way and will not abuse the process to dry up deal flow as the previous administration did.

    Slater Doubles Down on “America First Antitrust”

    • In her first public address as the assistant attorney general of the Antitrust Division, delivered at Notre Dame Law School, Slater echoed her own earlier statements regarding the new administration’s interest in promoting populist or “America First” antitrust policies.
    • “America First Antitrust” will support the needs of “forgotten” workers and consumers, small businesses, manufacturing, and family-owned agribusiness, according to Slater.
    • She went on to say that deregulation and transparency are key to these efforts, asserting that federal regulations impede the benefits of a free market, and that antitrust enforcement should be understandable to everyone, even farmers in Indiana or Iowa.

    As the Trump administration’s approach to antitrust takes shape through political appointments, policy statements, speeches, and enforcement actions, McDermott’s antitrust team continues to track new developments. We are providing important updates on issues pertinent to clients. Stay tuned for more at-a-glance reviews of relevant policy as it is being created.

    View our earlier insights on antitrust under the Trump administration.

    Authors

    Jon B. Dubrow

    Partner

    Washington, DC

    Michelle Lowery

    Partner

    Los Angeles, Chicago

    Megan C. Ingram

    Associate

    Washington, DC

    More insights